Excision with 5-mm margins for melanoma in situ that is less than 10 mm in size on low-risk body sites is associated with a low recurrence rate, according to a study published in JAMA Dermatology.
Health Professionals
Study uncovers the role of NETO2-mediated regulation in melanoma progression
Cong Peng and others at the Department of Dermatology, Xiangya Hospital, Central South University, China, conducted a study titled “NETO2 promotes melanoma progression via activation of the Ca2+/CaMKII signaling pathway," which investigated the role of Neuropilin and tolloid-like 2 (NETO2) in melanoma, a deadly form of skin cancer.
Treatment Algorithm for Stage IIB and Beyond Melanoma
Allison Betof Warner, MD, PhD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss treatment practices for patients with stage IIB and beyond melanoma.
Adjuvant Dabrafenib Plus Trametinib for Stage III BRAF V600–Mutated Melanoma: Final Results of the COMBI-AD Trial
Georgina V. Long, MD, PhD, of the Melanoma Institute Australia and the University of Sydney, and colleagues reported the final follow-up analysis of the phase III COMBI-AD trial at the 2024 ASCO Annual Meeting (Abstract 9500) and published their findings in The New England Journal of Medicine.